News & articles

AOP Orphan and PharmEssentia announced its latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera  On June 25, 2017 at the 22nd Congress of European Hematology Association (EHA) conference held in Spain, AOP Orphan Pharmaceuticals AG of Austria and Taipei, Taiwan headquartered PharmEssentia announced the latest results from three of their clinical studies on Ropeginterferon… Read More »BREAKING NEWS ON P1101

In an abstract submission to the academic journal Leukemia, Hans Hasselbach and colleagues describe CALR as a good target for development of an immunotherapy treatment for MPN. This is following up on the 2013 discovery of the CALR mutation, which accounts for the majority of JAK2 negative MPN patients.  Click here to read the abstract… Read More »RESEARCH NEWS: CALR DESCRIBED AS IMMUNOTHERAPY TARGET

MPN Research Foundation (MPNRF) and Patient Empowerment Network (PEN) have partnered together for a series of Digital Sherpa Workshops to be held in Charlotte, NC and Southwestern Florida in September 2017 to promote Blood Cancer Awareness Month. CONNECT with other MPN patients like you LEARN about MPN and other health resources BECOME more tech-savvy GET… Read More »DIGITAL SHERPA WORKSHOPS

July 26, 2017 The MPN Research Foundation is proud to announce the five winners of its 2017 Challenge Grant program. This is a combined effort with the Leukemia & Lymphoma Society. The projects selected were vetted by a review committee of MPN scientists including MPNRF’s Scientific Advisory Board. They reflect the priorities of the Foundation… Read More »MEET THE 2017 MPN CHALLENGE GRANT WINNERS

A MPN Landmark Survey funded by Incyte Corporation has been published!  Key information from the MPN LANDMARK SURVEY is now available for review and sharing. It includes a summary of the findings and some interviews with the MPN LANDMARK SURVEY steering committee members. The patient-friendly summary includes separate surveys of patients and physicians about MF, PV,… Read More »MPN LANDMARK SURVEY

ASU and the Mayo Clinic are seeking MPN cancer patients, ages 18 and up to participate in a research study. The purpose of the research is to determine the feasibility and preliminary effects of a mobile application-based health intervention on symptom burden (i.e., pain, fatigue, depression, anxiety, and sleep) and quality of life in Myeloproliferative… Read More »ASU AND MAYO CLINIC SEEK PARTICIPANTS FOR MOBILE APP SYMPTOM TRACKING

This week the FDA approved a novel and exciting curative therapy for Acute Lymphoblastic Leukemia. The drug company Novartis’  Kymriah, also known as tisagenlecleucel, is what is known as Chimeric Antigen Receptor Therapy, or CAR-T, in which a patient’s own cells are extracted, re-engineered as cancer-fighting mini-machines and re-introduced to the patient. Results were demonstrated in a… Read More »WHAT DOES THE APPROVAL OF KYMRIAH MEAN FOR MPN PATIENTS?

In a few days, the  month will change to September, which is recognized nationally as Blood Cancer Awareness Month. While you are already aware of MPNs, or myeloproliferative neoplasms, there are many factors indirectly but adversely affecting people living with Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. A few we hear from patients frequently are: Friends or family… Read More »WHAT DOES AN AWARENESS CAMPAIGN HAVE TO DO WITH PV, ET AND MF?

To view the Abstract pg this article please click here.

April 11, 2018Chicago, IL and Australia The MPN (Myeloproliferative Neoplasms) Research Foundation (MPNRF) and MPN Alliance Australia (MPN AA) are proud to announce a research partnership focused on the MPN Interferon Initiative. MPNRF and MPN AA are both patient advocacy organizations who work on behalf of patients with myeloproliferative neoplasms, a group of rare, chronic… Read More »MPN ALLIANCE AUSTRALIA AND MPN RESEARCH FOUNDATION PARTNER TO SUPPORT RESEARCH